What to Expect From the Upcoming Dialogue IPO

The upcoming Dialogue IPO is set to be a big one, as Canadian investors look for more telemedicine options on the TSX.

The telemedicine space is booming right now.

Vancouver-based Well Health Technologies has provided investors with a near five-bagger over the past year. Other U.S. players like Teladoc have similarly seen impressive stock price appreciation.

Accordingly, investors are eyeing what could be a highly sought-after IPO in Canada. It’s expected that Montreal-based Dialogue Health Technologies Inc. will go public shortly.

Similar to its aforementioned peers, the company operates in the telemedicine space. Dialogue designs specialized software solutions for telemedicine visits. The offerings include a mobile-based application that links doctors and patients.

Indeed, there’s higher demand than ever for this type of innovation in the healthcare sector, especially in light of the recent pandemic. However, investors seem to be bullish on the potential for a transformative, structural change to a traditional in-person industry. Indeed, the tentacles of technology are far-reaching today.

So, let’s look at what the IPO details are, and why investors are getting excited right now.

Dialogue IPO significantly oversubscribed

Having a vastly oversubscribed IPO is a good thing. Indeed, in Dialogue’s case, investors appear willing to line up around the block for these shares.

The company had to increase its initial public offering to $12 a share. This comes after receiving an overwhelming response from investors during the company’s marketing period.

Dialogue set out with an initial offering range between $9 and $12 a share. The amount the company wanted to raise was $100 million, and it received orders encompassing $1 billion. Indeed, any IPO that is 10 times oversubscribed is a hot one. Thus, there’s some speculation this IPO could open much higher upon the open of public trading. Dialogue has a consortium of big Canadian banks leading the deal and looks to be ready to hit the market soon.

Should investors buy in?

As of right now, Dialogue’s oversubscribed IPO looks like it could be the best-performing one in Canada in a while — at least, based on the initial data put forward.

Dialogue’s red herring prospectus reveals that the company has experienced a substantial amount of growth due to the ongoing pandemic. In 2020, this company’s online health service segment generated revenue of $29 million. This represented a three-fold increase from $10 million the year prior. It now provides this service to 2.5 million Canadians via four top Canadian group insurers.

This company is engaged in the provision of occupational health and safety services. Furthermore, it purchased an employee-assistance-program seller based in Canada. These two takeovers have been instrumental in strengthening Dialogue’s top line. In 2020, Dialogue’s annual recurring revenue stood at $60 million at the beginning of this year.

Indeed, these acquisitions have been a major boost for the company’s long-term top line. Furthermore, following the acquisitions, it appears that there’s ample growth on the horizon.

As far as IPOs go, this is one I’ll have my eye on. I would highly recommend investors add this stock to their watch list, if they’re not anticipating getting in early.

Fool contributor Chris MacDonald has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Teladoc Health.

More on Tech Stocks

moving into apartment
Tech Stocks

Canada’s Smart Money Is Piling Into This TSX Leader

Major institutional investors are loading up on this Canadian tech stock after blowout growth. Here is why the smart money…

Read more »

man in bowtie poses with abacus
Dividend Stocks

What the Average Canadian TFSA Looks Like at Age 50

See what the average Canadian TFSA looks like at age 50 and how CNR, Constellation Software, and VFV could support…

Read more »

Senior uses a laptop computer
Dividend Stocks

A Canadian Dividend Stock Down 35% to Buy and Hold for Retirement

Rogers’ 13% dip has pushed its yield above 4%, and management expects a big jump in free cash flow.

Read more »

A patient takes medicine out of a daily pill box.
Tech Stocks

1 Undervalued Canadian Stock to Buy and Hold Forever

This small-cap healthcare software stock keeps winning long-term contracts and just got a governance stamp of approval.

Read more »

crisis concept, falling stairs
Tech Stocks

1 Canadian Stock Down 45% I’d Buy and Hold Now

Constellation Software’s 45% plunge looks scary, but its revenue and cash flow are still growing fast.

Read more »

The TFSA is a powerful savings vehicle for Canadians who are saving for retirement.
Dividend Stocks

3 Canadian Stocks Well-Suited for a Long-Term Buy-and-Hold TFSA

A simple TFSA mix of Shopify, CN Rail, and Royal Bank aims to compound for decades while keeping every gain…

Read more »

Women's fashion boutique Aritzia is a top stock to buy in September 2022.
Tech Stocks

What Are the Best High-Growth Canadian Stocks to Buy Now?

Three Canadian growth stocks look compelling, but they’re priced for success, so gradual buying and position sizing matter.

Read more »

Couple working on laptops at home and fist bumping
Tech Stocks

How Much Canadians Usually Have in an RRSP by Age 45

See how your RRSP compares at age 45, and why a growth stock like CGI, powered by Q2 earnings, could…

Read more »